PathAI’s software uses machine learning and deep learning công nghệ to lớn identify disease biomarkers & predict treatment reactions, advancing and improving the work of pathologists và pharmaceutical researchers. (Pixabay)

If its hundreds of millions in venture funding và wide-ranging cadre of big-named partners are any indication, PathAI’s (ahem) path forward appears to lớn be paved in gold.

Bạn đang xem:

The five-year-old startup develops artificial-intelligence-based technologies lớn augment the work of pathologists. The platkhung uses machine learning & deep learning khổng lồ improve sầu both diagnostic & treatment capabilities by identifying disease biomarkers and predicting how individual patients will respond lớn various treatments.

To continue this development, PathAI has raised $165 million in a newly closed series C. The financing was co-led by D1 Capital Partners và Kaiser Permanente. Another dozen investors joined in the round, including Bristol Myers Squibb, Labcorp và Merck’s Global Health Innovation Fund.

The latest funding round follows PathAI’s series B, which initially closed in April 2019 with $60 million from a group of investors led by General Atlantic. About six months later, the round officially closed with an extra $15 million from the Merck Global Health Innovation Fund & Bristol Myers Squibb.

RELATED: Merck, BMS chip in khổng lồ PathAI"s series B, bringing total khổng lồ $75M

PathAI’s newest influx of funds will be put toward growing its commercial reach và the platform’s clinical retìm kiếm capabilities. The Boston-based startup is planning to lớn adapt its technology for use in new disease indications beyond its current work in the diagnosis and treatment of cancer and nonalcoholic steatohepatitis, or NASH.

Xem thêm: The Transporter - Người Vận Chuyển Chỉ Của Jason Statham

The financing will also help bring PathAI’s platsize inkhổng lồ all facets of biopharmaceutical retìm kiếm and drug development, from the identification of potential drug targets khổng lồ clinical trials và the commercialization process.

PathAI currently works with pharmaceutical researchers, diagnostic developers and digital pathology companies in its efforts khổng lồ build out & deploy its AI-powered công nghệ for disease diagnosis and treatment.

RELATED: AI cancer pathology developer Paige nets $100M in venture capital funding

Labcorp, for example, expanded its existing collaboration with PathAI earlier this year. The extended partnership will see Labcorp use PathAI’s algorithms to identify disease-specific biomarkers và the biomarker-positive patients who will respond best lớn certain treatments khổng lồ improve sầu clinical trials managed by Labcorp’s drug development arm.

Through the collaboration, Labcorp will also explore the possibility of using those same AI algorithms khổng lồ create và commercialize companion diagnostic devices lớn accompany the drugs in development.

And, last fall, PathAI & longtime partner Gilead unveiled results of a joint study demonstrating that PathAI’s machine learning giải pháp công nghệ was able to lớn analyze liver biopsies to accurately predict the progression of NASH và chronic hepatitis B vi khuẩn infection và determine how effective sầu standard treatments might be, indicating the AI’s potential use in ultimately improving diagnosis & treatment of liver disease.

venture capital (VC) artificial intelligence digital pathology drug development diagnostics PathAI series C